G. Driessens

发表

SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma

S. Rorive, I. Salmon, Sylvain Brohée, 2014, Nature.

Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo

Yan Zheng, T. Gajewski, F. Locke, 2012, The Journal of experimental medicine.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery

L. Tenenbaum, V. Préat, C. Bruyns, 2011, Cancer Immunology, Immunotherapy.

Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors

B. J. Van den Eynde, L. Pilotte, V. Stroobant, 2019, Cancer Immunology Research.

β-catenin does not regulate memory T cell phenotype

Yan Zheng, T. Gajewski, G. Driessens, 2010, Nature Medicine.

Long live sox2: sox2 lasts a lifetime.

C. Blanpain, G. Driessens, Grégory Driessens, 2011, Cell stem cell.

Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies

N. Wald, M. Cragg, M. Bagot, 2020, Molecular Cancer Therapeutics.

A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours

P. Carmeliet, J. Haigh, S. Loges, 2011, Nature.

Beta-catenin negatively regulates peripheral T cell activation

T. Gajewski, G. Driessens, 2009 .

β-Catenin Inhibits T Cell Activation by Selective Interference with Linker for Activation of T Cells–Phospholipase C-γ1 Phosphorylation

F. Gounari, Yan Zheng, T. Gajewski, 2011, The Journal of Immunology.

b-Catenin Inhibits T Cell Activation by Selective Interference with Linker for Activation of T Cells–Phospholipase C-g1 Phosphorylation

F. Gounari, T. Gajewski, F. Locke, 2010 .

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

C. Dillon, Xianxian Zheng, M. Kraus, 2018, Molecular Cancer Therapeutics.

Defining the mode of tumour growth by clonal analysis

Benjamin D. Simons, C. Blanpain, B. Simons, 2012, Nature.

Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells

T. Gajewski, C. Cham, G. Driessens, 2008, European journal of immunology.

Costimulatory and coinhibitory receptors in anti‐tumor immunity

T. Gajewski, G. Driessens, Gregory Driessens, 2009, Immunological reviews.

Conditional Deletion of PTEN in Peripheral T Cells Augments TCR-Mediated Activation but Does Not Abrogate CD28 Dependency or Prevent Anergy Induction

Yan Zheng, T. Gajewski, F. Locke, 2013, The Journal of Immunology.

Prevent Anergy Induction but Does Not Abrogate CD 28 Dependency or T Cells Augments TCR-Mediated Activation Conditional Deletion of PTEN in Peripheral Driessens and

Yan Zheng, T. Gajewski, G. Driessens, 2013 .

15-Deoxy-12,14-prostaglandin J2 inhibits interferon gamma induced MHC class II but not class I expression on ARPE cells through a PPAR gamma independent mechanism.

C. Bruyns, D. Bléro, G. Driessens, 2006, Prostaglandins & other lipid mediators.

Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration

P. Stordeur, C. Bruyns, T. Velu, 2008, Cancer Immunology, Immunotherapy.

Synergy Between Dendritic Cells and GM–CSF-secreting Tumor Cells for the Treatment of a Murine Renal Cell Carcinoma

A. Zlotta, C. Bruyns, T. Velu, 2009, Journal of immunotherapy.

Assessment of In Vivo Chemotherapy‐Induced DNA Damage in a p53‐Mutated Rat Tumor by Micronuclei Assay

L. Harsan, C. Bruyns, T. Velu, 2003, Annals of the New York Academy of Sciences.

Highly Successful Therapeutic Vaccinations Combining Dendritic Cells and Tumor Cells Secreting Granulocyte Macrophage Colony-stimulating Factor

C. Bruyns, T. Velu, G. Driessens, 2004, Cancer Research.

A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library

M. Biancalana, A. Koide, S. Koide, 2009, Proceedings of the National Academy of Sciences.

Abstract 3261: EOS100850, a non-brain penetrant highly selective A2Areceptor antagonist, uniquely maintains high potency within the adenosine rich tumor microenvironment

X. Leroy, B. Gomes, G. Driessens, 2019, Immunology.

Abstract 1683: A novel adenosine A2A receptor antagonist optimized for high potency in adenosine-rich tumor microenvironment boosts antitumor immunity

C. Quéva, V. Bol, B. Gomes, 2017 .

The Combination of Anti-Tigit and Lenalidomide Promotes Synergistic Myeloma-Specific Immunity after ASCT

G. Hill, G. Driessens, L. Holmberg, 2021, Blood.

Micronuclei to detect in vivo chemotherapy damage in a p53 mutated solid tumour

L. Harsan, C. Bruyns, T. Velu, 2003, British Journal of Cancer.

TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice

S. Furlan, D. Sester, G. Hill, 2022, The Journal of clinical investigation.

Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors

Paolo Vicini, Deepak Dalvie, Chad Ray, 2016 .

Abstract LB-291: EOS100850, an insurmountable and non-brain penetrant A2A receptor antagonist, inhibits adenosine-mediated T cell suppression, demonstrates anti-tumor activity and exhibits best-in class characteristics

N. Wald, X. Leroy, G. Driessens, 2018 .